Nexstim has received MDR certification for its diagnostic system NBS 6 in the EU. The certification enables marketing and sales of the system for preoperative mapping of the brain's speech and motor cortex. NBS 6 launched in 2023 for the treatment of depression and chronic neuropathic pain in the EU and for the treatment of severe depression in the US. The system's modular design allows customers to order combinations of therapy and diagnostic modules.
|
Published October 9, 2025
Nexstim receives MDR certification for NBS 6
Text:
News Desk [email protected]
Notes
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
Egetis reports positive results from the ReTRIACt study
Mikael Dolsten withdraws his nomination to Novo's board
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account